Savantia AG · Switzerland
Board and C-level counsel for the life-science industry.
Savantia is a Swiss advisory firm founded by two operators who have built, financed and led life-science companies. We take active board seats and senior advisory mandates — not observer roles.
Approach
Judgement earned in the operating seat, applied in the board room.
Most advisory is commentary. Ours is accountability: we sit on boards, chair committees, and carry the same fiduciary duty as the directors around us. That changes the quality of the advice.
We work with a deliberately small number of companies at a time — biotech, pharmaceuticals, generics, CDMO and the funds that back them — from Series A through public markets and exit.
Advisory
Six areas we focus on
Board of Directors & senior advisory roles
Non-executive directorships, chair and committee roles on public and private boards. Governance that holds up under investor and regulator scrutiny.
Industry partnerships
Licensing, co-development and manufacturing alliances — structured so the smaller party keeps its leverage.
Mergers & acquisitions
Buy- and sell-side counsel from target thesis through diligence, negotiation and the integration year that decides whether the deal worked.
Capital markets & private financing
Venture and growth rounds, cross-over financing, IPO readiness and life as a listed company on NASDAQ, NYSE and the Danish, Luxembourg and Warsaw stock exchanges.
General management
CEO-level sparring on strategy, organisation and succession across biotech, branded pharma and generics — including turnarounds and scale-ups.
Drug development strategy
From basic research to clinical trials: indication selection, development plans and the evidence a board needs to fund the next stage.
Founders
Two careers, one seat at the table.
Dr. Claudia Mitchell
Founder & Chief Executive Officer
Twenty-five years in cell and gene therapy across four continents, with senior positions spanning academia, non-profit research, biotech, large pharmaceutical companies and venture capital.
More than two decades of scientific and executive leadership: building biotech start-ups, setting medical research strategy and leading development programmes from basic research into the clinic. EY Entrepreneur of the Year, life sciences.
Markus Sieger
Founder & Chairman
Swiss entrepreneur and C-level executive with a career built in emerging industries — media, IT, digital, pharmaceuticals and venture capital — and markets across Central and Eastern Europe, the US and Switzerland.
Chief Executive of Polpharma Group from 2016 to 2025: one of the leading pharmaceutical companies in Central and Eastern Europe, headquartered in Amsterdam, with some 7,000 employees and revenues above €1.2 billion. Non-executive director on public boards in New York, Luxembourg and Warsaw, and on private company boards.
Mandates
Current board seats and advisory engagements of the founders.
Public company boards
Private company boards
Advisory roles
Private equity & venture
Contact
Tell us what the board is wrestling with.
We reply to every serious enquiry personally, usually within two working days. Conversations are confidential by default.